Interactive Investor

Neil Woodford’s company to close but FSCS not looking at compensation claims

16th October 2019 12:19

Tom Bailey from interactive investor

Loading

Share on

Neil Woodford has stepped down as manager of Patient Capital trust and announced that Woodford Investment Management will be closing its doors

Following the decision to wind up Woodford Equity Income fund, Neil Woodford has stepped down from his role as manager for Woodford Patient Capital trust and announced that Woodford Investment Management will also be closing down.

In a statement, the fund manager said he had “taken the highly painful decision to close Woodford Investment Management”.

He continued: “I personally deeply regret the impact events have had on individuals who placed their faith in Woodford Investment Management and invested in our funds.”

Along with the company’s closure, it was also announced that Woodford would be stepping down as manager of Patient Capital while his remaining fund, Woodford Focused Income, will be wound up.

In a letter posted on the London Stock Exchange, the trust’s board noted: “In light of recent events, Woodford Investment Management Limited ("WIM") has today served notice of termination in relation to its role as Portfolio Manager”.

What happens to Patient Capital now is unclear.

As previously noted, the board has already been considering the option of removing Woodford as manager.

In its letter on the LSE website, the board said it “expects to be in a position to announce details of the new management arrangements shortly”.

Adrian Lowcock, head of personal investing at Willis Owen, welcomes Woodford’s decision to step down from managing the trust.

Mr Lowcock notes: “Woodford’s decision to step down from the board of Woodford Patient Capital Trust was no doubt a hard decision, but given Woodford’s presence had become a distraction to the trust, it was also the right thing to do.

“Investors’ money is ring-fenced and will remain invested in the respective funds and in the underlying investments.”

The news has seen the share price of Patient Capital plummet.

At open, the trust fell by 10%. It has since recovered slightly and is now down (at the time of writing) roughly 5%. Year-to-date the trust is down 55%, and it sits on a discount of over 40%.

Ryan Hughes, head of active portfolios at AJ Bell, says the closure of Woodford’s company was somewhat inevitable.

He notes: “Without the fees from the equity income fund and with no performance fee coming from the Patient Capital trust, it was difficult to see how the business could survive.”

It has since been announced that the Woodford Income Focus fund has also been suspended.  

Will investors get compensation?

In a statement to Moneywise, the Financial Services Compensation Scheme (FSCS) says it will not be investigating any compensation claims at the moment. 

This article first appeared on our sister website Money Observer

This article was originally published in our sister magazine Moneywise, which ceased publication in August 2020.

These articles are provided for information purposes only. Occasionally, an opinion about whether to buy or sell a specific investment may be provided by third parties. The content is not intended to be a personal recommendation to buy or sell any financial instrument or product, or to adopt any investment strategy as it is not provided based on an assessment of your investing knowledge and experience, your financial situation or your investment objectives. The value of your investments, and the income derived from them, may go down as well as up. You may not get back all the money that you invest. The investments referred to in this article may not be suitable for all investors, and if in doubt, an investor should seek advice from a qualified investment adviser.

Full performance can be found on the company or index summary page on the interactive investor website. Simply click on the company's or index name highlighted in the article.

Get more news and expert articles direct to your inbox

Sign up for a free research account to get the latest news and discussion, and create your own virtual portfolio.

Free Sign Up